Search

Displaying results 2661 - 2670 of 10000 in total
  1. Drug

    Dithiazanine

    go.drugbank.com/drugs/DB11516
    ApprovedVet approvedWithdrawn

    Dithiazanine is a highly potent anthelmintic, introduced in 1959 for the treatment of strongyloid worms and whipworms. However, its use is severely limited due to its toxicity. … Dithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032]

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    After the first cord blood transplant in 1988 in a patient with Fanconi anemia [A32220], the use of umbilical cord blood transplantation was increased in clinical settings. … Hemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use.

  3. Drug

    Dimetindene

    go.drugbank.com/drugs/DB08801
    ApprovedInvestigational

    Dimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.

  4. Drug

    Clofarabine

    go.drugbank.com/drugs/DB00631
    ApprovedInvestigational

    Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. … Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed.

    Categories: OCT2 Substrates with a Narrow Therapeutic Index, OAT3/SLC22A8 Substrates with a Narrow Therapeutic IndexSynonyms: Cl-F-Ara-A
  5. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    [L63814] Like other gadolinium agents it is paramagnetic, developing a magnetic moment in the scanner's field that alters the relaxation of nearby water protons and brightens tissues with abnormal vascularity … in the central nervous system and in the body.

  6. Drug

    Somatostatin

    go.drugbank.com/drugs/DB09099
    ApprovedInvestigationalWithdrawn

    [DB00104] is a long-acting analogue of somatostatin that inhibits the release of a number of hormones, and is clinically used to relieve symptoms of uncommon gastroenteropancreatic endocrine tumours, as … Prosomastatin is further process into two active forms, somatostatin-14 (SST-14) and somatostatin-28 (SST-28), an extended SST-14 sequence to the N-terminus [A20384].

  7. Drug

    REN-850

    go.drugbank.com/drugs/DB05912
    Experimental

    REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.

  8. Drug

    Gatifloxacin

    go.drugbank.com/drugs/DB01044
    ApprovedInvestigationalWithdrawn

    patients taking gatifloxacin compared to those on macrolide antibiotics. … Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Ibrexafungerp

    go.drugbank.com/drugs/DB12471
    Approved

    [A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349] … Ibrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast

  10. Drug

    Thiothixene

    go.drugbank.com/drugs/DB01623
    Approved

    A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.